Skip to main content
Log in

Ibrutinib: First Global Approval

  • R&D Insight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Ibrutinib (Imbruvica™) is a small molecule, first-in-class, once-daily, orally available, Bruton’s tyrosine kinase inhibitor that is under development for the treatment of B cell malignancies, including chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL), as well as multiple myeloma (MM), follicular lymphoma (FL) and Waldenstrom’s macroglobulinemia (WM). It has been developed by Pharmacyclics, Inc. and Janssen Biotech, Inc. Ibrutinib acts by blocking B-cell antigen receptor signalling, thereby reducing malignant proliferation of B cells and inducing cell death. Based chiefly on findings from a phase Ib/II study, ibrutinib has been approved in the USA for the treatment of MCL in previously treated patients and is one of the first approvals through the US FDA’s Breakthrough Therapy Designation Pathway. An application has been filed in the EU seeking regulatory approval in this indication. In both the USA and EU, further applications have been filed with regulatory bodies seeking approval for the use of ibrutinib in patients with previously treated CLL/small lymphocytic lymphoma (SLL). Phase III trials are underway worldwide to evaluate ibrutinib in the treatment of patients with CLL/SLL, DLBCL and MCL, and the agent is in phase II development for use in WM, FL and MM. This article summarizes the milestones in the development of ibrutinib leading to its first approval in MCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lymphoma Research Foundation. Non-Hodgkin lymphoma (NHL). 2012. http://www.lymphoma.org. Accessed 9 Nov 2013.

  2. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1922–2001. Blood. 2006;107(1):265–76.

    Article  CAS  PubMed  Google Scholar 

  3. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 2010;11(11):1074–85.

    Article  CAS  PubMed  Google Scholar 

  5. Chang JE, Kahl BS. Current status of targeted therapies for mantle cell lymphoma. Drugs. 2011;71:2307–26.

    Article  CAS  PubMed  Google Scholar 

  6. Danilov AV. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther. 2013;35(9):1258–70.

    Article  CAS  PubMed  Google Scholar 

  7. Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128–30.

    Article  CAS  PubMed  Google Scholar 

  8. Pharmacyclics, Inc. ImbruvicaTM (ibrutinib) capsules for oral use; US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205552s000lbl.pdf. Accessed 10 December 2013.

  9. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.

    Article  CAS  PubMed  Google Scholar 

  10. Pharmacyclics, Inc. New drug application filing for ibrutinib accepted in two B-cell malignancies by the U.S. FDA [media release]. Aug 29 2013. http://www.pharmacyclics.com.

  11. Pharmacyclics, Inc. New drug application for ibrutinib submitted to the U.S. FDA [media release]. Jul 10 2013. http://www.pharmacyclics.com.

  12. Celera Corp. Celera Corporation separates from Applera Corporation [media release]. Jul 1 2008. http://www.celera.com.

  13. Pharmacyclics, Inc. Celera Genomics announces sale of therapeutic programs to Pharmacyclics [media release]. Apr 10 2006. http://www.pharmacyclics.com.

  14. Celera Genomics. Celera Genomics reports first quarter fiscal 2006 results [media release]. Oct 27 2005. http://www.celera.com.

  15. Quest Diagnostics Inc. Quest Diagnostics successfully completes acquisition of Celera [media release]. May 17 2011. http://www.questdiagnostics.com.

  16. Pharmacyclics, Inc. Pharmacyclics announces collaboration with the National Cancer Institute to develop its novel Btk Inhibitor, PCI-32765 in hematologic malignancies [media release]. Aug 9 2011. http://www.pharmacyclics.com.

  17. WuXi PharmaTech Inc. WuXi Pharma to partner with Pharmacyclics [media release]. Nov 15 2013. http://www.wuxiapptec.com.

  18. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–49.

    Article  CAS  PubMed  Google Scholar 

  19. Honigberg LA, Smith AM, Loury DJ. A clinical trial of the Bruton’s tyrosine kinase inhibitor PCl-32765 in naturally occurring canine lymphoma [abstract no. 3740]. In: 100th Annual Meeting of the American Association for Cancer Research; Apr 18–22 2009; Denver.

  20. Honigberg L, Smith A, Chen J, et al. PCL-31523: an irreversible inhibitor of Bruton’s tyrosine kinase that disrupts B cell receptor signaling, is cytotoxic to B cell lymphomas, and is active in an animal arthritis model [abstract no. 5398]. In: 98th Annual Meeting of the American Association for Cancer Research; Apr 14–18 2007; Los Angeles.

  21. Ponader S, Chen SS, Buggy JJ, et al. Bruton’s tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9.

    Article  CAS  PubMed  Google Scholar 

  22. Nimbus Discovery. Nimbus Discovery IRAK4 inhibitors demonstrate synergistic effects with BTK iInhibitor ibrutinib [media release]. Dec 9 2012. http://www.nimbusdiscovery.com.

  23. Elias L, Chen J, Buggy J. BTK inhibitor ibrutinib inhibits breast cancer growth by inhibiting ErbB2 kinase [abstract no. C258]. In: 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 19–23 2013, Boston.

  24. Lobe CG, Allain MJ, Yang W. Activity of BTK and HDAC inhibitors alone and in combination in a mouse model of non-small cell lung cancer [abstract no. C243]. In: 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 19–23 2013, Boston.

  25. Vij R, Chang BY, Berdeja JG, et al. Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the Bruton tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM) [abstract no. 653]. In: 54th Annual Meeting of the American Society of Hematology; Dec 8–11 2012, Atlanta.

  26. Nathan F, Jeff S, Sonali S, et al. A phase I trial of BTK inhibitor PCI-32765 in patients with relapsed non-Hodgkin’s lymphoma: evidence of antitumor activity [abstract no. 0893]. In: 15th Congress of the European Haematology Association; Jun 10–13 2010, Barcelona.

  27. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

    Article  CAS  PubMed  Google Scholar 

  28. Wiestner A, Farooqui M, Valdez J, et al. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17p deletion. Hematol Oncol. 2013;31:98.

    Google Scholar 

  29. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  30. Brown JR, Barrientos JC, Barr PM, et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study [abstract no. 525]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.

  31. Burger JA, Keating MJ, Wierda WG, et al. Efficacy and safety of ibrutinib in combination with rituximab in high-risk CLL patients. Hematol Oncol. 2013;31:193–4.

    Google Scholar 

  32. Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induced a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase II trial in 40 patients [abstract no. 675]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.

  33. Farooqui M, Aue G, Valdez J, et al. Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p [abstract no. 673]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.

  34. O’Brien S, Furman RR, Fowler N, et al. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study [abstract no. 4163]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013; New Orleans.

  35. Wilson WH, Gerecitano JF, Goy A, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract no. 686]. In: 54th Annual Meeting of the American Society of Hematology; Dec 8–11 2012, Atlanta.

  36. deVos S, Wilson WH, Gerecitano JF, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results [abstract no. S1180]. In: 18th Congress of the European Haematology Association; Jun 13–16 2013, Stockholm.

  37. Treon S, Tripsas C, Yang G, et al. A prospective, multicentre, phase II study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenstrom’s macroglobulinemia [abstract no. 067]. Hematol Oncol. 2013;31:119.

    Article  Google Scholar 

  38. Treon SP, Tripsas K, Yang G, et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulimemia [abstract no. 251]. In: 55th Annual Meeting of the American Society of Hematology; Dec 7–10 2013, New Orleans.

  39. Abbott, Inc. Abbott to collaborate with Janssen and Pharmacyclics on development of companion test for investigational leukemia therapy [media release]. Feb 21 2013. http://www.abbott.com.

  40. US Food and Drug Administration. Imbruvica. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/205552Orig1s000ltr.pdf. Accessed 9 December 2013.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fiona Cameron.

Additional information

This profile has been extracted and modified from the Adis R&D Insight drug pipeline database. Adis R&D Insight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cameron, F., Sanford, M. Ibrutinib: First Global Approval. Drugs 74, 263–271 (2014). https://doi.org/10.1007/s40265-014-0178-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0178-8

Keywords

Navigation